23andMe Holding Co. (ME)
NASDAQ: ME · Real-Time Price · USD
3.150
-0.280 (-8.16%)
At close: Nov 20, 2024, 4:00 PM
3.180
+0.030 (0.95%)
Pre-market: Nov 21, 2024, 7:28 AM EST
23andMe Holding Co. Revenue
23andMe Holding Co. had revenue of $44.07M in the quarter ending September 30, 2024, a decrease of -11.86%. This brings the company's revenue in the last twelve months to $193.26M, down -28.47% year-over-year. In the fiscal year ending March 31, 2024, 23andMe Holding Co. had annual revenue of $219.64M, down -26.66%.
Revenue (ttm)
$193.26M
Revenue Growth
-28.47%
P/S Ratio
0.40
Revenue / Employee
$332,062
Employees
582
Market Cap
86.10M
Revenue Chart
Revenue History
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
P3 Health Partners | 1.48B |
Rockwell Medical | 98.92M |
OptimizeRx | 88.18M |
MDxHealth | 84.71M |
Clearside Biomedical | 7.70M |
Werewolf Therapeutics | 3.39M |
Chimerix | 159.00K |
ME News
- 1 day ago - 23andMe and Mirador Therapeutics Enter Into Strategic Research Collaboration to Advance Mirador's Precision Medicines for Immunology & Inflammation - GlobeNewsWire
- 8 days ago - 23andMe Holding Co. (ME) Q2 2025 Earnings Call Transcript - Seeking Alpha
- 8 days ago - 23andMe cuts 40% of staff in restructuring - TechCrunch
- 8 days ago - What's happening with 23andMe? Mass layoffs and restructuring are the latest blow for the embattled DNA testing company - Fast Company
- 8 days ago - 23andMe reports sales decline day after announcing plans to cut 40% of workforce - CNBC
- 8 days ago - Genetic testing firm 23andMe cuts 40% of its workforce amid financial struggles - The Guardian
- 8 days ago - 23andMe's stock turns lower after company posts its latest quarterly loss - Market Watch
- 9 days ago - 23andMe Lays Off 40% of Staff, Shuts Drug Development Business - WSJ